FindTrial
Sign In

Effect of Desidustat on Bone Mineral Density in Chronic Kidney Disease Patients

Effect of Desidustat on Bone Mineral Density and Safety in Chronic Kidney Disease Patients: Single Arm, Observational Study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/102315
Enrollment
98
Registered
2026-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N189- Chronic kidney disease, unspecified

Interventions

Intervention1: Nil: Nil

Sponsors

Dr KIRTI OJHA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1. Patient at high-risk for bone fracture 2. Patient on denosumab or alendronate or any other bisphosphonate 3. Prior treatment with bisphosphonate or denosumab within 6 months 4. Immunosuppression or life-threatening illnesses or conditions compromising patient safety 5. Participation in other drug studies within the last 3 months 6. If any participant could not complete the study duration of 6 months, he/she will be excluded from the study

Design outcomes

Primary

MeasureTime frame
To observe change in bone mineral density (BMD) Measured by Dual Energy X-ray Absorptiometry (DXA) T-scoreTimepoint: 6 months—

Secondary

MeasureTime frame
1. To observe the proportion of patients with treatment emergent adverse eventsTimepoint: baseline, 3 months, 6 months;2. To observe mean change in hemoglobin level and serum ferritin levels in chronic kidney disease patients on desidustatTimepoint: baseline, 3 months, 6 months—

Countries

India

Contacts

Public ContactDr KIRTI OJHA

AIIMS Bathinda

kwatragagandeep@gmail.com9815588600

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026